 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
BOSTON LIFE SCIEN, (BLSI) Stock Rating Learn More
| Our Overall Rating on BOSTON LIFE SCIEN, BLSI is Not Available | | Boston Life Sciences, Inc. engages in the research and development of biopharmaceutical products for the diagnosis and treatment of central nervous system (CNS) diseases, Parkinsons disease (PD), and cancer. Its primary product candidate ALTROPANE is a nuclear medicine imaging agent that is being developed as an aide in the diagnosis of Parkinsonian Syndromes in patients with tremor and as an aide in the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The company is conducting second Phase II trial of ALTROPANE for the diagnosis of ADHD in adults and second Phase III trial of ALTROPANE to differentiate Parkinsonian from nonParkinsonian tremors. Boston Life Sciences is developing Inosine, a nerve growth factor, which promotes axon outgrowth in CNS cells and is undergoing pre-clinical studies. Its other early stage product candidates include FLUORATEC and O-1369 targeted at CNS diseases, as well as Troponin, an anti-angiogenic agent, as a treatment for cancer, which is in pre-clinical development stage. Boston Life Sciences is based in Boston, Massachusetts. | | Our Not Available Rating on BLSI was issued on 11/20/2008 |
BOSTON LIFE SCIEN Technical Rating
|
|
|
|
